Fig. 2.

(A) Net graph of mean migraine days, (B) Net graph of responder rate, and (C) Net graph of adverse events. In each network graph, the size of each node is proportional to the total number of randomized participants (sample size) allocated to the corresponding treatment across all trials, and the width of each line is proportional to the total number of randomized controlled trials evaluating the corresponding treatment comparison.

EP100, eptinezumab 100 mg; EP300, eptinezumab 300 mg; ER140, erenumab 140 mg; ER70, erenumab 140 mg; FM, fremanezumab (monthly); FQ, fremanezumab (quarterly); F900, fremanezumab 900 mg; PLC, placebo; G120, galcanezumab 120 mg; G240, galcanezumab 240 mg.